PharmaNet Development Group Expands European Consulting Services with the Addition of Bengt Danielsson M.D., Ph.D.

PharmaNet Development Group, Inc. (the "Company”) (NASDAQ: PDGI), a leading provider of global drug development services, announced today that it has appointed Bengt Danielsson, M.D., Ph.D., to the position of Vice President, PharmaNet Consulting. Dr. Danielsson joins the Company from the Swedish Medical Product Agency where he served as Scientific Director/Professor in Pharmacology and Toxicology for the past three years. During that time he also served as a member and the EU Pharmacology & Toxicology representative of the EMEA/CHMP Innovative Medicine Task Force group and a member and Swedish representative of the CHMP/EU Safety and CHMP/EU Cell-based Products working parties. "We are extremely pleased to have someone of Dr. Danielsson’s stature join PharmaNet Development Group,” commented Dr. James Burns, Senior Vice President, PharmaNet Consulting. "He adds to an already impressive team of experts in our drug development consulting practice, which includes a number of senior former-FDA officials, and will bring significant technical and regulatory experience to assist our clients who are developing products in Europe.” Dr. Burns continued, "This appointment affirms the Company’s commitment to providing superior consulting services through its experienced consultants who have established reputations in their fields.” Prior to the Swedish Medical Product Agency, Dr. Danielsson worked for Astra AB and AstraZeneca where he held progressive positions of responsibility, most recently as Global Director, Clinical Interface Support and Global Science Leader, Reproductive Toxicology. He is also an Adjunct Professor in Pharmaceutical Toxicology at Uppsala University. About PharmaNet Consulting PharmaNet Consulting Group offers a broad range of experience and product development expertise to help clients anticipate and address challenges throughout the clinical development process. The group is comprised of senior-level consulting professionals, including former FDA officials, with proven product-development expertise, experience working with international regulatory agencies and the proven ability to provide insight to help anticipate emerging industry and regulatory trends. About PharmaNet Development Group, Inc. PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. The Company offers clinical-development solutions including early and late stage consulting services, Phase l clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,400 employees and more than 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com. Forward-Looking Statements Certain statements made in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, industry trends and information; the Company's ability to determine its impairment charges and costs of discontinued operations; whether the Company will achieve its estimated value relating to discontinued operations; developments with respect to the SEC's inquiry and securities class action lawsuits and derivative lawsuits; the Company’s ability to successfully achieve and manage the technical requirements of specialized clinical trial services, while complying with applicable rules and regulations; regulatory changes; changes affecting the clinical research industry; a reduction of outsourcing by pharmaceutical and biotechnology companies; the Company’s ability to compete internationally in attracting clients in order to develop additional business; the Company’s evaluation of its backlog and the potential cancellation of contracts; its ability to retain and recruit new employees; its clients' ability to provide the drugs and medical devices used in its clinical trials; the Company’s future stock price; the Company’s assessment of its effective tax rate and tax allowance; the Company’s financial guidance; the Company’s future effective tax rate; the Company’s anticipated capital expenditures; the Company’s costs associated with compliance of Section 404 of the Sarbanes-Oxley Act; the impact on the Company of foreign currency transaction costs and the effectiveness of any hedging strategies it implements; and the national and international economic climate as it affects drug development operations. Further information can be found in the Company’s risk factors contained in its Annual Report on Form 10-K for the year ended December 31, 2006 and its most recent Quarterly Report on Form 10-Q. The Company does not undertake to update the disclosures made herein, and you are urged to read our filings with the Securities and Exchange Commission.